Rare condition

Hyperlipoproteinemia type 1

ORPHA:411 ↗

Search all Hyperlipoproteinemia type 1 trialsAlert me when a trial opens

studies recruiting now

as of 7 Sept 2026

studies registered in total

as of 7 Sept 2026

countries with a recruiting site

as of 7 Sept 2026

27 Jul 2026

most recent study posted

among recruiting studies

Recruiting trials

RecruitingPhase 3NCT07727538

A Study of Olezarsen for the Treatment of Familial Chylomicronemia Syndrome (FCS) in Pediatric Participants

Sponsor Ionis Pharmaceuticals, Inc.Where United States (4 sites)Studying OlezarsenUpdated 26 Aug 2026

See details

RecruitingPhase 1 / Phase 2NCT07223658

Study of ARO-DIMERPA in Adult Participants With Mixed Hyperlipidemia

Sponsor Arrowhead PharmaceuticalsWhere Australia, Canada, Georgia +1 (17 sites)Studying ARO-DIMERPA, PlaceboUpdated 18 Aug 2026

See details

RecruitingPhase 3NCT06597006

Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia

Sponsor Novartis PharmaceuticalsWhere United States, Austria, China +8 (19 sites)Studying Inclisiran, PlaceboUpdated 24 Jul 2026

See details

RecruitingPhase 1NCT07491172

A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias

Sponsor CRISPR Therapeutics AGWhere United States, Australia, New Zealand +1 (19 sites)Studying CTX310Updated 23 Jul 2026

See details

RecruitingPhase 2NCT05816343

Long Term Efficacy and Safety of Orlistat for Type 1 Hyperlipoproteinemia

Sponsor University of Texas Southwestern Medical CenterWhere United States (1 site)Studying Orlistat, PlaceboUpdated 21 Jul 2026

See details

Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.

See all 10 recruiting studies

Where recruiting studies are running

Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.

Australia Austria Canada China Georgia Germany Greece Malaysia Netherlands New Zealand South Africa Taiwan Turkey (Türkiye)United Kingdom United States

Keep watching

Get an email when a new Hyperlipoproteinemia type 1 study opens.

One email a day at most. Unsubscribe with one click.

Used only for these alerts. Privacy.

Support

Patient organisations

We do not yet list a dedicated organisation for this condition. The directories below are the best route.

NORD ↗GARD ↗Orphanet ORPHA:411 ↗

About Hyperlipoproteinemia type 1

RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations.

Orphanet expert page ↗GARD (NIH) ↗

Treatments being studied

2 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.

Phase 2Orlistat (Alli)

Phase 2Slx-4090

Related conditions

Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).